While Ascendis Pharma A/S ADR has underperformed by -1.74%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ASND rose by 19.49%, with highs and lows ranging from $171.34 to $111.09, whereas the simple moving average jumped by 21.01% in the last 200 days.
On April 16, 2025, RBC Capital Mkts started tracking Ascendis Pharma A/S ADR (NASDAQ: ASND) recommending Outperform. A report published by UBS on January 07, 2025, Initiated its previous ‘Buy’ rating for ASND. Oppenheimer also Upgraded ASND shares as ‘Outperform’, setting a target price of $180 on the company’s shares in a report dated September 05, 2024. TD Cowen June 25, 2024d the rating to Buy on June 25, 2024, and set its price target from $156 to $175. Stifel initiated its ‘Buy’ rating for ASND, as published in its report on May 31, 2024. Jefferies’s report from December 20, 2023 suggests a price prediction of $150 for ASND shares, giving the stock a ‘Buy’ rating. Credit Suisse also rated the stock as ‘Neutral’.
Analysis of Ascendis Pharma A/S ADR (ASND)
Further, the quarter-over-quarter increase in sales is 25.27%, showing a positive trend in the upcoming months.
Ascendis Pharma A/S ADR’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. Taking into account the quick ratio of the company, currently set at 0.84, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and ASND has an average volume of 517.64K. On a monthly basis, the volatility of the stock is set at 6.48%, whereas on a weekly basis, it is put at 4.31%, with a gain of 4.38% over the past seven days. Furthermore, long-term investors anticipate a median target price of $212.79, showing growth from the present price of $167.47, which can serve as yet another indication of whether ASND is worth investing in or should be passed over.
How Do You Analyze Ascendis Pharma A/S ADR Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.78%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 106.72% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ASND shares are owned by institutional investors to the tune of 106.72% at present.
